Construction of the "Patient-Centered"Molecular Pathology Diagnostic Center

• Conditions: Cancer

• Registration Number: NCT01311388
• Lead Sponsor: Taipei Medical University WanFang Hospital

Brief Summary

The investigators want to achieve the goal of diagnosis in early phase, accurate treatment and existence for a long period in order to screen in early phase, diagnose in clinical trial, choose treatment and evaluate prognosis of cancers by establishing molecular pathology tools.

Detailed Description

This research is going to discuss the biomarker expression of common malignant neoplasm (tumor)among Taiwanese, such as large intestine rectal cancer, breast cancer, prostate gland cancer, lung cancer, oral cancer, gastric cancer, liver cancer, cervical cancer, cancer of the womb, ovarian cancer, carcinoma of urinary bladder, kidney cancer and so on.

The investigators hope to find the biomarker of common tumors among Taiwanese in order to develop the tools of tumor screening, diagnosis, treatment methods and prediction prognosis

Study Timeline

• Study Start: 2010-08
• Status Verified: 2011-03
• Study First Submitted: 2011-03-06
• Study First Submitted QC: 2011-03-08
• Last Update Submitted: 2011-03-08
• Study First Posted: 2011-03-09
• Last Update Posted: 2011-03-09
• Study Completion: 2013-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

• above 20 years old
• all kinds of cancer patients

Exclusion Criteria

• under 20 years old
• none cancer patients

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

TMU-CECR; 🇨🇳 Taipei, Taiwan